Please assess the completion status of the following clinical trial:

Trial Title: Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~All of the following conditions must apply to the prospective patient at screening prior to participation:~* Histologically verified prostate cancer, and either currently on Zoladex or without any current or no past usage of any ADT~* Between 18 and 75 years of age~* Capable of reading and understanding Norwegian, and able to provide informed consent~* Treating oncologist/ study medical doctor´s (KMR) approval for participation~* Signed informed consent must be obtained and documented according to Good Clinical Practice (GCP), and national/local regulations.~Exclusion Criteria:~Patients will be excluded from the study if they meet any of the following criteria:~* Routine resistance training (\>1 weekly session, last six months)~* Treated with Warfarin, or if seponation of acetylsalicylic acid is not recommended~* Conditions where heavy resistance exercise is contraindicated:~  * Unregulated hypertension~ * Unstable angina pectoris~ * Recent myocardial infarction (\<1 year)~ * Cardiac arrhythmia~ * Chronic obstructive pulmonary disease~ * Severe asthma~ * Recent stroke (\<1 year)~ * Epilepsy~ * Insulin-dependent diabetes mellitus~ * Unstable bone lesions with increased risk of fractures~* Conditions where patients ability to complete the training sessions is challenged:~  * Uncontrolled pain~ * Severe arthritis~ * Scheduled hip or knee replacement~ * Pathologic fractures last six months~ * Amputations~ * Walker or wheelchair user~* Mentally incompetent conditions:~  * Severe anxiety or depression~ * Dementia~ * Known alcoholism or substance abuse~ * Mentally retarded

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ADT group (Type: EXPERIMENTAL): Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
- No-ADT group (Type: NO_INTERVENTION): Prostate cancer patients without any history of receiving any form of androgen deprivation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).